Jigar Shah, MD
Hematology & Oncology · Clarksville, TNNPI 1013936079
Payments from drug & device makers
Across 17 payments — averaging $291.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$2K
- Bayer$2K
- US Oncology Corporate, Inc.$621
- Cardinal Health 110 LLC$275
- Novocure GmbH$250
- Daiichi Sankyo Inc.$88
- plus $50 from 2 others
What the payments were for
- Consulting fees$1,77536%
- Speaking & faculty fees$2,21045%
- Travel & lodging$2355%
- Food & beverage$68214%
- Education$120%
- Gifts$331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 2 | $1,995 |
| Bayer | 3 | $1,669 |
| US Oncology Corporate, Inc. | 3 | $621 |
| Cardinal Health 110 LLC | 1 | $275 |
| Novocure GmbH | 1 | $250 |
| Daiichi Sankyo Inc. | 4 | $88 |
| Tersera Therapeutics LLC | 2 | $38 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,947 in reported general payments places this provider in the 30th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $149,068 |
| XareltoRivaroxaban | 160 | $131,615 |
| BrukinsaZanubrutinib | 11 | $86,179 |
| Imatinib Mesylate | 18 | $30,352 |
| RetacritEpoetin Alfa-Epbx | 12 | $21,364 |
| Abiraterone Acetate | 12 | $19,769 |
| Azacitidine | 17 | $9,914 |
| Risedronate Sodium | 13 | $1,398 |
| Leucovorin Calcium | 12 | $1,184 |
| Ondansetron OdtOndansetron | 26 | $1,154 |
| Letrozole | 48 | $1,123 |
| Warfarin Sodium | 28 | $690 |
| Alendronate Sodium | 55 | $540 |
| Fluorouracil | 14 | $527 |
| Tamoxifen Citrate | 14 | $486 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Clarksville
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
- Krish PatelNashville$14.2M
- Kathryn BeckermannFranklin$13.6M
- Denise YardleyNashville$13.2M
- Todd BauerNashville$10.9M
- Bertrand AnzChattanooga$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.